Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene

被引:14
作者
Baldewijns, Marcella M. [1 ]
van Vlodrop, Iris J. H. [1 ]
Smits, Kim M. [2 ]
Vermeulen, Peter B. [3 ,4 ]
Van den Eynden, Gert G. [3 ,4 ]
Schot, Fiona [1 ]
Roskams, Tania [5 ]
van Poppel, Hein [6 ]
van Engeland, Manon [1 ]
de Brune, Adriaan P. [1 ]
机构
[1] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Pathol, Maastricht, Netherlands
[2] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Epidemiol, Maastricht, Netherlands
[3] Gen Hosp St Augustinus, Ctr Oncol, Antwerp, Belgium
[4] Univ Antwerp, Univ Antwerp Hosp, Pathol Lab, Translat Canc Res Grp, Edegem, Belgium
[5] Univ Hosp Leuven, Dept Pathol, Louvain, Belgium
[6] Univ Hosp Leuven, Dept Urol, Louvain, Belgium
关键词
VHL; angiogenesis; renal cell carcinoma; TUMOR-SUPPRESSOR GENE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GROWTH-FACTOR EXPRESSION; VHL GENE; KIDNEY CANCER; MESSENGER-RNA; PROMOTER HYPERMETHYLATION; CONSTITUTIVE ACTIVATION; FACTOR (HIF)-1-ALPHA; NETHERLANDS COHORT;
D O I
10.3233/CLO-2009-0482
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: von Hippel-Lindau (VHL) inactivation is common in sporadic clear cell renal cell carcinomas (ccRCC). pVHL is part of the ubiquitin ligase complex that targets the alpha subunits of hypoxia-inducible transcription factor (HIF) for degradation under well-oxygenated conditions. In the absence of wild-type pVHL, as observed in VHL patients and most sporadic ccRCCs, constitutive upregulation of HIF results in transcriptional activation of angiogenesis-related genes, such as VEGF. Differences in angiogenic activity within the group of ccRCCs were reported and strong genotype-phenotype correlations were found in patients with VHL disease, raising a question about the importance of VHL inactivation status in angiogenic behaviour and tumour progression. Methods: To address this question, we investigated the influence of VHL mutation (direct sequencing)/hypermethylation (methylation-specific PCR) on angiogenesis/tumour parameters (immunohistochemistry) in 150 patients with sporadic ccRCC. Results: We found no significant association between VHL mutation or methylation and angiogenesis/tumour parameters. Conclusion: These data indicate that tumour progression and angiogenesis are not directly influenced by VHL alterations and that additional genetic/epigenetic events should be considered to explain the diverse angiogenic and proliferative behaviour during tumour progression.
引用
收藏
页码:371 / 382
页数:12
相关论文
共 58 条
[1]   High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile [J].
Baldewijns, M. M. ;
Thijssen, V. L. ;
Van den Eynden, G. G. ;
Van Laere, S. J. ;
Bluekens, A. M. ;
Roskams, T. ;
van Poppel, H. ;
De Bruine, A. P. ;
Griffioen, A. W. ;
Vermeulen, P. B. .
BRITISH JOURNAL OF CANCER, 2007, 96 (12) :1888-1895
[2]   Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer [J].
Banks, RE ;
Tirukonda, P ;
Taylor, C ;
Hornigold, N ;
Astuti, D ;
Cohen, D ;
Maher, ER ;
Stanley, AJ ;
Harnden, P ;
Joyce, A ;
Knowles, M ;
Selby, PJ .
CANCER RESEARCH, 2006, 66 (04) :2000-2011
[3]  
Battagli C, 2003, CANCER RES, V63, P8695
[4]  
Blancher C, 2001, CANCER RES, V61, P7349
[5]  
BRAUCH H, 1994, WORLD J UROL, V12, P162
[6]   Role of HIF-1α or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis [J].
Carmeliet, P ;
Dor, Y ;
Herbert, JM ;
Fukumura, D ;
Brusselmans, K ;
Dewerchin, M ;
Neeman, M ;
Bono, F ;
Abramovitch, R ;
Maxwell, P ;
Koch, CJ ;
Ratcliffe, P ;
Moons, L ;
Jain, RK ;
Collen, D ;
Keshet, E .
NATURE, 1998, 394 (6692) :485-490
[7]   Promoter hypermethylation profile of kidney cancer [J].
Dulaimi, E ;
Ibanez de Caceres, I ;
Uzzo, RG ;
Al-Saleem, T ;
Greenberg, RE ;
Polascik, TJ ;
Babb, JS ;
Grizzle, WE ;
Cairns, P .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :3972-3979
[8]   SOMATIC MUTATIONS OF THE VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE IN NONFAMILIAL CLEAR-CELL RENAL-CARCINOMA [J].
FOSTER, K ;
PROWSE, A ;
VANDENBERG, A ;
FLEMING, S ;
HULSBEEK, MMF ;
CROSSEY, PA ;
RICHARDS, FM ;
CAIRNS, P ;
AFFARA, NA ;
FERGUSONSMITH, MA ;
BUYS, CHCM ;
MAHER, ER .
HUMAN MOLECULAR GENETICS, 1994, 3 (12) :2169-2173
[9]   MUTATIONS OF THE VHL TUMOR-SUPPRESSOR GENE IN RENAL-CARCINOMA [J].
GNARRA, JR ;
TORY, K ;
WENG, Y ;
SCHMIDT, L ;
WEI, MH ;
LI, H ;
LATIF, F ;
LIU, S ;
CHEN, F ;
DUH, FM ;
LUBENSKY, I ;
DUAN, DR ;
FLORENCE, C ;
POZZATTI, R ;
WALTHER, MM ;
BANDER, NH ;
GROSSMAN, HB ;
BRAUCH, H ;
POMER, S ;
BROOKS, JD ;
ISAACS, WB ;
LERMAN, MI ;
ZBAR, B ;
LINEHAN, WM .
NATURE GENETICS, 1994, 7 (01) :85-90
[10]   Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene [J].
Gnarra, JR ;
Zhou, SB ;
Merrill, MJ ;
Wagner, JR ;
Krumm, A ;
Papavassiliou, E ;
Oldfield, EH ;
Klausner, RD ;
Linehan, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :10589-10594